BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22536446)

  • 1. DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.
    Galbán S; Lemasson B; Williams TM; Li F; Heist KA; Johnson TD; Leopold JS; Chenevert TL; Lawrence TS; Rehemtulla A; Mikkelsen T; Holland EC; Galbán CJ; Ross BD
    PLoS One; 2012; 7(4):e35857. PubMed ID: 22536446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
    Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
    Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery.
    Hadjipanayis CG; Fellows-Mayle W; Deluca NA
    Mol Ther; 2008 Nov; 16(11):1783-8. PubMed ID: 18728637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
    Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines.
    Oancea-Castillo LR; Klein C; Abdollahi A; Weber KJ; Régnier-Vigouroux A; Dokic I
    Cancer Biol Ther; 2017 Jun; 18(6):400-406. PubMed ID: 28494176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
    Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
    Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
    Tran AN; Lai A; Li S; Pope WB; Teixeira S; Harris RJ; Woodworth DC; Nghiemphu PL; Cloughesy TF; Ellingson BM
    Neuro Oncol; 2014 Mar; 16(3):414-20. PubMed ID: 24305712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study.
    Saito K; Mukasa A; Narita Y; Tabei Y; Shinoura N; Shibui S; Saito N
    Neurol Med Chir (Tokyo); 2014; 54(4):272-9. PubMed ID: 24257502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging.
    Viel T; Schelhaas S; Wagner S; Wachsmuth L; Schwegmann K; Kuhlmann M; Faber C; Kopka K; Schäfers M; Jacobs AH
    PLoS One; 2013; 8(7):e67911. PubMed ID: 23861829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
    Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
    Ashby LS; Smith KA; Stea B
    World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
    Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R;
    Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma.
    Wang Y; Chen X; Zhang Z; Li S; Chen B; Wu C; Wang L; Zhang X; Wang J; Chen L; Jiang T
    Neurosurg Rev; 2014 Jan; 37(1):73-8. PubMed ID: 23912878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
    Biau J; Chautard E; De Schlichting E; Dupic G; Pereira B; Fogli A; Müller-Barthélémy M; Dalloz P; Khalil T; Dillies AF; Durando X; Godfraind C; Verrelle P
    Radiat Oncol; 2017 Dec; 12(1):197. PubMed ID: 29212499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy with and without temozolomide in elderly patients with glioblastoma.
    Niyazi M; Schwarz SB; Suchorska B; Belka C
    Strahlenther Onkol; 2012 Feb; 188(2):154-9. PubMed ID: 22231634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
    Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
    NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
    Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.